Every 8-K that Ikena Oncology, Inc. (IKNA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IKNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IKNA filings page.
ImageneBio, Inc. (formerly Ikena Oncology, Inc.) has filed an 8-K to confirm that on 25 Jul 2025 it closed the previously announced merger with Cayman-based Inmagene Biopharmaceuticals. Two wholly owned Cayman merger subsidiaries were used to combine Inmagene into the Delaware parent, leaving Inmagene as a wholly owned subsidiary.
Immediately after closing, the registrant changed its corporate name to “ImageneBio, Inc.” and updated its Nasdaq listing to the new ticker IMA. The company furnished, under Item 7.01 (Reg FD), a press release (Exhibit 99.1) announcing completion of the transaction; the release is incorporated by reference but not deemed “filed.” No consideration details, pro-forma financials or other quantitative information are provided in this report.
Ikena Oncology filed an 8-K announcing a 1-for-12 reverse stock split of its common stock, effective at the start of trading on 28 Jul 2025. Every 12 pre-split shares will convert into 1 post-split share; fractional shares will be paid out in cash based on Nasdaq’s 24 Jul 2025 closing price. The split will reduce outstanding shares from approximately 48.2 million to roughly 4 million, while authorised share capital and the $0.001 par value remain unchanged; exercise prices and share counts under outstanding equity awards will be adjusted proportionately.
At the same time the company will rebrand as ImageneBio, Inc., adopt the new ticker IMA, and switch CUSIP to 45175G207, continuing to trade on the Nasdaq Capital Market. Computershare is serving as exchange agent, and shareholders whose holdings are in book-entry or brokerage accounts need not take any action.
The filing is limited to corporate-action details and a comprehensive forward-looking-statement section that highlights risks surrounding the planned merger with Inmagene Biopharmaceuticals, the concurrent financing, and completion of the reverse split. No financial performance metrics were provided.